ライフサイエンスコーパス: pulmonary embolus

1 ina, arrhythmia, symptomatic hypotension, or pulmonary embolus).

2 (60 mg) had cycle 1 dose-limiting toxicity (pulmonary embolus).

3 and thrombosis type (deep vein thrombosis or pulmonary embolus).

4 No patient developed a pulmonary embolus.

5 adverse event as a result of an asymptomatic pulmonary embolus.

6 ntestinal leak, small bowel obstruction, and pulmonary embolus.

7 tient died during treatment as a result of a pulmonary embolus.

8 ing in pregnant patients suspected of having pulmonary embolus.

9 rapy: one as a result of sepsis and one of a pulmonary embolus.

10 rombosis, and 1 eventually developed a major pulmonary embolus.

11 d as Fontan conduit/right atrial thrombus or pulmonary embolus.

12 One death occurred related to a pulmonary embolus (0.4%).

13 s of specific diseases, RRs were as follows: pulmonary embolus 1.87 (95% CI 1.13-3.07, p=0.01 [includ

14 Grade 4 adverse events included pulmonary embolus (1), vomiting and constipation (1), an

15 oronary syndrome (8.0% vs 9.2% vs 15.8%), or pulmonary embolus (1.9% vs 2.4% vs 6.8%) and to require

16 The most common serious adverse events were pulmonary embolus (11 [1.6%] in the albumin group vs 8 [

17 , 100-350 mA; 0.35-second tube rotation) and pulmonary embolus (64 sections at 1.25 mm, 140 kVp, 645

18 boembolism (VTE) (deep venous thrombosis and pulmonary embolus) after splenectomy was 4.3% compared w

19 Two patients had a pulmonary embolus and four had Greenfield filters in the

20 g deep-vein thrombosis but a reduced rate of pulmonary embolus and heparin-induced thrombocytopenia a

21 These findings were driven by lower rates of pulmonary embolus and heparin-induced thrombocytopenia a

22 'triple rule-out' for myocardial infarction, pulmonary embolus, and aortic dissection, with an eye to

23 l sequelae, sequelae of gastric perforation, pulmonary embolus, and disease progression.

24 Chest pain, pulmonary embolus, and mental status change cases posed

25 enous thrombosis not otherwise specified, or pulmonary embolus during the study period, and who had b

26 Her course was complicated by another saddle pulmonary embolus, heparin-induced thrombocytopenia, and

27 in 23, pneumonia in 21, Hemothorax in 12 and pulmonary embolus in 8.Median/5-year survival were 20.7

28 d to cause an extra breast cancer,stroke, or pulmonary embolus in about 6 per 1000 users aged 50-59 a

29 oducible, and non-lethal means to assess for pulmonary embolus in the non-human primate.

30 the patient expired as a result of an acute pulmonary embolus in the setting of bilateral hip fractu

31 (composite of infection, venous thrombosis, pulmonary embolus, inability to aspirate blood, mechanic

32 le sex, age, comorbidity, and surgical risk (pulmonary embolus, leak, death, incisional hernia) than

33 Pulmonary embolus {odds ratio [OR] 12.34 [95% confidence

34 cipants who received tofersen, one died from pulmonary embolus on day 137, and one from respiratory f

35 ll complications OR 0.72 (95% CI 0.55-0.93), pulmonary embolus OR 0.29 (95% CI 0.11-0.73), pneumonia

36 puncture or laceration (APL), postoperative pulmonary embolus or deep venous thrombosis (PEDVT), for

37 d deep vein thrombosis (DVT) alone in 49.7%, pulmonary embolus (PE) alone in 25.4%, DVT plus PE in 13

38 Pulmonary embolus (PE) was identified in 44 recipients (

39 /Q) scan interpretation algorithms for acute pulmonary embolus (PE).

40 hysician extender rounds reduces the risk of pulmonary embolus, pneumonia, and death when compared to

41 stoperative adverse events (including death, pulmonary embolus, pneumonia, deep wound infection, and

42 high-risk clinical scenarios: postoperative pulmonary embolus, pneumothorax, myocardial infarction,

43 ated with perioperative death included leak, pulmonary embolus, preoperative weight, and hypertension

44 venous studies examined deep vein thrombosis/pulmonary embolus prevention (42%) or venous ulceration

45 tient died 3 days after surgery, following a pulmonary embolus (spleen weight 500 g, mortality 1/108,

46 Major complications (reintubation, pulmonary embolus, stroke, renal failure, coma, cardiac

47 DSA allows more confident detection of pulmonary embolus than does CFA, with no loss in diagnos

48 er a rapid bedside echocardiogram suggesting pulmonary embolus, thrombolytic therapy was administered

49 ments combined) were cellulitis (two cases), pulmonary embolus (two cases), and deep-vein thrombosis

50 ific diagnoses (acute myocardial infarction, pulmonary embolus, upper gastrointestinal bleed), and co

51 n the development of deep vein thrombosis or pulmonary embolus (venous thromboembolism [VTE]).

52 Pulmonary embolus was diagnosed in 357 patients (24.9%).

53 Pulmonary embolus was not suspected at CT in the remaini

54 ing in pregnant patients suspected of having pulmonary embolus, with considerable variability in thei